XTAI
4746
Market cap184mUSD
Oct 08, Last price
48.95TWD
1D
1.87%
1Q
-10.68%
Jan 2017
-50.81%
IPO
-47.34%
Name
Formosa Laboratories Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services. In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support. Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.
Key people
Chairman of the Board, General Manager · since 2013
Hank Chen
Deputy General Manager-Production and Environment & Health & Safety Division · since 1997
Hengui Huang
Deputy General Manager-Quality Assurance Division · since 2014
Kevin Lee
Deputy General Manager-Research & Development Division · since 2019
Josh Lin
Deputy General Manager-Engineering Division · since 2009
Chien Hsing Lin
Deputy General Manager-Legal & Strategy Planning Division · since 2020
Jessica Liou
Deputy General Manager-Marketing & Sales Division · since 1996
Michelle Lo
Deputy General Manager-Finance Division, Head of Corporate Governance · since 2022
Jeff Sung
Deputy General Manager-Injectable Division · since 2018
J.C. Wung
Deputy General Manager-Quality Control Division · since 2021
Fannie Yang
Deputy General Manager-Operational Support Division · since 2020
Qianfei Lin
Chief Information Security Officer · since 2023
Pei Fang
Director · since 2023
Yi Kan Hu
Director · since 2022
Jianhong Li
Director · since 2014
Director · since 2016
Lujie Wang
Director · since 2008
Hongmin Xie
Director · since 2006
Zhihan Zhong
Director · since 2008
Yi Fen Chen
Independent Director
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||